Cargando…
Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment
Sunitinib is a small molecular inhibitor of tyrosine kinases and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumour after disease progression or intolerance to imatinib therapy. Here, we describe biochemical and pathological response of prostate cancer in a patient wi...
Autores principales: | Song, Ik Chan, Lim, Jae Sung, Yun, Hwan Jung, Kim, Samyong, Kang, Dae Young, Lee, Hyo Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299431/ https://www.ncbi.nlm.nih.gov/pubmed/19773269 http://dx.doi.org/10.1093/jjco/hyp110 |
Ejemplares similares
-
Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
por: Hwang, Eugene, et al.
Publicado: (2010) -
Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017) -
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
por: Kim, Ho Cheol, et al.
Publicado: (2013) -
Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017) -
Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)